Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Market Cap	331.60B
Revenue (ttm)	17.11B
Net Income (ttm)	232.18M
Shares Out	n/a
EPS (ttm)	1.76
PE Ratio	1,428.23
Forward PE	43.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122
Average Volume	106
Open	126.48
Previous Close	121.60
Day's Range	124.80 - 126.48
52-Week Range	67.16 - 132.40
Beta	0.30
RSI	56.25
Earnings Date	Nov 6, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1LN34

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD